

Miguel FERNÁNDEZ-HUERTA
CV_Versión_23/06/2022
[Orcid](#) • [ResearchGate](#) • [LinkedIn](#)

EXPERIENCIA PROFESIONAL

- **Especialista en Microbiología Clínica** **2021 - act.**
Hospital Universitario de Navarra. Servicio de Microbiología. Pamplona, España.
Ocupación
 - Microbiología molecular, secuenciación (estrategias Sanger y secuenciación de nueva generación), micología.
- **Especialista en Microbiología Clínica** **2020 - 2021**
Hospital Universitario de Bellvitge. Servicio de Microbiología. Barcelona, España.
Ocupación
 - Micobacteriología, microbiología molecular.
- **Especialista en Microbiología Clínica** **2019**
Hospital de la Santa Creu i Sant Pau. Servicio de Microbiología. Barcelona, España.
Ocupación
 - Infección genitourinaria y respiratoria.

FORMACION

- **Doctorado en Microbiología (Cum Laude)** **2018 - 2021**
Departamento de Genética y Microbiología. Universitat Autònoma de Barcelona (UAB). Barcelona, España.
“Epidemiología y resistencias antibióticas en *Mycoplasma genitalium*”
Directores: Dr. Tomàs Pumarola y Dr. Oscar Quijada.
- **Postgrado en Estadística en Ciencias de la Salud** **2016 - act.**
Departamento de Psicobiología y Metodología de las Ciencias de la Salud. Universitat Autònoma de Barcelona (UAB). Barcelona, España.
- **Especialización BIR en Microbiología Clínica** **2015 - 2019**
Hospital Universitario Vall d’Hebron. Servicio de Microbiología. Barcelona, España.
Estancias académicas
 - 2018 Departamento de Microbiología y Control de la Infección.
Statens Serum Institut (SSI). Copenhagen, Dinamarca.
Supervisor: Prof. Jorgen-Skov Jensen.
- **Grado en Bioquímica** **2010 - 2014**
Facultad de Ciencias. Universidad de Navarra (UN). Pamplona, España.
Estancias académicas
 - 2013 - 2014 Departamento de Genética Molecular.
Groningen Biomolecular Sciences and Biotechnology Institute (GBB).
University of Groningen (RUG). Groningen, Países Bajos.
Supervisor: Prof. Jan-Willem Veening.
 - 2012 Departamento de Microbiología Molecular
Centro de Biología Molecular Severo Ochoa (CBMSO).
Universidad Autónoma de Madrid (UAM)-CSIC. Madrid, España.
Supervisor: Prof. Wilfried Meijer.

1. **Fernández-Huerta M**, Pich OQ, Espasa M. *Mycoplasma* and *Ureaplasma* spp. in clinical practice of anogenital infections. Rev Esp Quimioter. 2022 [letter to editor]
2. Trobajo-Sanmartín C, Martínez-Baz I, Miqueleiz A, **Fernández-Huerta M**, Burgui C, Casado I, Baigorriá F, Navascués A, Castilla J, Ezpeleta C. Differences in transmission between SARS-CoV-2 alpha (B.1.1.7) and delta (B.1.617.2) variants. Microbiol Spectr. 2022
3. Càmarà J, González-Díaz A, Barrabeig I, **Fernández-Huerta M**, Calatayud L, Niubó J, Martí S, Angeles Domínguez M, Ardanuy C. SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: a role for the quantification of circulating antibodies. Vaccine. 2022
4. **Fernández-Huerta M**, Salmerón P, Hernández-Hermida Y, Andrés C, Niubó J, Calatayud L, Angeles Domínguez M, Pumarola T, Ardanuy C, Antón A, Càmarà J. Multicenter clinical evaluation of a novel transcription-mediated amplification assay for SARS-CoV-2 molecular testing. Enferm Infecc Microbiol Clin. 2022
5. Trobajo-Sanmartín C, Miqueleiz A, Portillo ME, **Fernández-Huerta M**, Navascués A, Castilla J, Ezpeleta C. Utility of a commercial RT-qPCR assay to detect SARS-CoV-2 gene variations as an indicator of lineages. J Virol Methods. 2022
6. Trobajo-Sanmartín C, Miqueleiz A, Portillo ME, **Fernández-Huerta M**, Navascués A, Sola Sara P, Moreno PL, Ordoñez GR, Castilla J, Ezpeleta C. Emergence of SARS-CoV-2 variant B.1.575.2 containing the E484K mutation in the spike protein in Pamplona (Spain) May-June 2021. Journal of Clinical Microbiology. 2021
7. Martínez-Baz I, Trobajo-Sanmartín C, Miqueleiz A, Guevara M, **Fernández-Huerta M**, Burgui C, Casado I, Portillo ME, Navascués A, Ezpeleta C, Castilla J; Working Group for the Study of COVID-19 in Navarre; Investigators, other members of the Working Group for the Study of COVID-19 in Navarre. Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Eurosurveillance. 2021
8. Fernández-Naval C, Arando M, Espasa M, Antón A, **Fernández-Huerta M**, Silgado A, Pinatar C, Zarzuela F, González-López JJ, Serra-Pladevall J, Sulleiro E, Pumarola T, Vall-Mayans M, Esperalba J. Multilocus sequence typing of *Treponema pallidum* subsp. *pallidum* in Barcelona. Future Microbiology. 2021
9. **Fernández-Huerta M**, Moreto C, Vila-Olmo N, García de Cara EI, Basaez MC, Santin M, Alcaide F. Evaluation of the fully-automated chemiluminescence analyzer LIAISON XL for the performance of the QuantiFERON-TB Gold Plus assay in a low-incidence tuberculosis area. Journal of Clinical Microbiology. 2021
10. Berenguer J, Borobia AM, Ryan P, Rodríguez-Baño J, Bellón JM, Jarrín I, Carratalà J, Pachón J, Carcas AJ, Yllescas M, Arribas JR, **COVID-19@Spain and COVID@HULP Study Groups**. Development and validation of a prediction model for 30-day mortality in hospitalized patients with COVID-19: the COVID-19 SEIMC score. Thorax. 2021
11. **Fernández-Huerta M***, Serra-Pladevall J, Pumarola T, Pich OQ, Espasa M. Comment on: Lower *mgpB* diversity in macrolide-resistant *Mycoplasma genitalium* infecting men visiting two sexually transmitted infection clinics in Montpellier, France. Journal of Antimicrobial Chemotherapy. 2021
12. Solanich X†, **Fernández-Huerta M†**, Basaez C, Antolí A, Rocamora-Blanch G, Corbella X, Santin M, Alcaide F. Clinical significance of indeterminate QuantiFERON-TB Gold Plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome. Journal of Clinical Medicine. 2021
13. Gutiérrez-Gutiérrez B, Del Toro MD, Borobia AM, Carcas A, Jarrín I, Yllescas M, Ryan P, Pachón J, Carratalà J, Berenguer J, Arribas JR, Rodríguez-Baño J, **REIPI-SEIMC COVID-19 group and COVID@HULP groups**. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. Lancet Infectious Diseases. 2021
14. Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, Yllescas M, Arriba JR, **COVID-19@Spain Study Group**. Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clinical Microbiology and Infection. 2020
15. Vizarraga D, Kawamoto A, Matsumoto U, Illanes R, Pérez-Luque R, Martín J, Mazzolini R, Bierge P, Pich OQ, Espasa M, Sanfeliu I, Esperalba J, **Fernández-Huerta M**, Scheffer MP, Pinyol J, Frangakis AS, Lluch-Senar M, Mori S, Shibayama K, Kenri T, Kato T, Namba K, Fita I, Miyata M, Aparicio D. Immunodominant proteins P1 and P40/P90 from human pathogen *Mycoplasma pneumoniae*. Nature Communications. 2020
16. **Fernández-Huerta M***, Salmerón P, Silgado A, Espasa M, Pumarola M, Tulsiani-Drud S, Barberá MJ, Hoyos-Mallecot Y, Serra-Pladevall J. Clinical evaluation of the ResistancePlus MG Flexible test on the GeneXpert Infinity-48s instrument: a near-patient assay for simultaneous detection of *Mycoplasma genitalium* and macrolide resistance. Diagnostic Microbiology and Infectious Disease. 2020
17. **Fernández-Huerta M***, Serra-Pladevall J, Esperalba J, Moreno-Mingorance A, Fernández-Naval C, Barberá MJ, Aparicio D, Pich OQ, Pumarola T, Jensen JS, Espasa M. Single-locus-sequence-based typing of the *mgpB* gene reveals transmission dynamics in *Mycoplasma genitalium*. Journal of Clinical Microbiology. 2020
18. **Fernández-Huerta M***, Serra-Pladevall J, Pich OQ, Barberá MJ, Espasa M. From resistance-guided to risk-guided antimicrobial therapy in *Mycoplasma genitalium*. Sexually Transmitted Diseases Journal. 2020 [commentary]
19. **Fernández-Huerta M***, Barberá MJ, Serra-Pladevall J, Esperalba J, Martínez-Gómez X, Centeno C, Pich OQ, Pumarola T, Espasa M. *Mycoplasma genitalium* and antimicrobial resistance: a comprehensive review. International Journal of STD & AIDS. 2020 [review article]
20. **Fernández-Huerta M***, Serra-Pladevall J, Esperalba J, Pich OQ, García-Pérez JN, Espasa M. RE: A case of rectal *Ureaplasma* infection and implications for testing in young men who have sex with men: the P18 Cohort Study, by Abbott et al. (LGBT Health 2017;4:161-163). LGBT Health. 2020 [letter to editor]
21. **Fernández-Huerta M***, García-Pérez JN, Pich OQ, Espasa M. *Mycoplasma genitalium*: an emerging pathogen at the STI units. Piel. 2020 [artículo en castellano] [review article]
22. **Fernández-Huerta M**, Esperalba J, Serra-Pladevall J, Espasa M. *Mycoplasma genitalium* and fluoroquinolone resistance detection using a novel qPCR assay in Barcelona, Spain. Enfermedades Infecciosas y Microbiología Clínica. 2019 [scientific letter]
23. Fernández-Naval C, Arando M, Espasa M, Antón A, **Fernández-Huerta M**, Silgado A, Jimenez I, Villatoro AM, González-López JJ, Serra-Pladevall J, Sulleiro E, Pumarola T, Vall-Mayans M, Esperalba J. Enhanced

- molecular typing and macrolide and tetracycline resistance mutations of *Treponema pallidum* in Barcelona. Future Microbiology. 2019
24. **Fernández-Huerta M**, Bodiyaadu K, Esperalba J, Bradshaw CS, Serra-Pladevall J, Garland SM, Fernández-Naval C, Jensen JS, Pumarola T, Ebeyan S, Lundgren M, Tan LY, Espasa M, Murray GL. Multicenter clinical evaluation of a novel multiplex real-time PCR (qPCR) assay for detection of fluoroquinolone resistance in *Mycoplasma genitalium*. Journal of Clinical Microbiology. 2019
 25. **Fernández-Huerta M**, Serra-Pladevall J, Esperalba J, Espasa M. *Mycoplasma genitalium* and fluoroquinolone resistance: from genotype to phenotype. Enfermedades Infecciosas y Microbiología Clínica. 2019 [artículo en castellano] [letter to editor]
 26. **Fernández-Huerta M**, Barberá MJ, Esperalba J, Fernández-Naval C, Vall M, Arando M, Serra-Pladevall J, Broto C, Zarzuela F, Rando A, Pumarola T, Espasa M. *Mycoplasma genitalium* and macrolide resistance among asymptomatic people visiting a point of care service for rapid STI screening: a cross-sectional study. Sexually Transmitted Infections Journal. 2019
 27. **Fernández-Huerta M**, Espasa M. *Mycoplasma genitalium* co-infection with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* among asymptomatic patients: the silent wick for macrolide resistance spread. Sexually Transmitted Infections Journal. 2019 [scientific letter]
 28. **Fernández-Huerta M**, Vall M, Fernández-Naval C, Barberá MJ, Arando M, López L, Andreu A, Pumarola T, Serra-Pladevall J, Esperalba J, Espasa M. *Mycoplasma genitalium* macrolide resistance update: rate among a 2016-2017 cohort of patients in Barcelona, Spain. Enfermedades Infecciosas y Microbiología Clínica. 2019
 29. **Fernández-Huerta M**, Zarzuela F, Barberá MJ, Arando M, Esperalba J, Rodríguez V, Vall M, Falcó V, García-Pérez JN, Pumarola T, Espasa M, Sulleiro E. Sexual transmission of intestinal parasites and other enteric pathogens among men who have sex with men presenting gastrointestinal symptoms in an STI Unit in Barcelona, Spain: a cross-sectional study. American Journal of Tropical Medicine and Hygiene. 2019
 30. **Fernández-Huerta M***, Escobar R, Monforte V, Rodríguez V. Microbial contamination of liposomal amphotericin B nebulizer devices in lung transplant patients. Enfermedades Infecciosas y Microbiología Clínica. 2019 [scientific letter]
 31. **Fernández-Huerta M**, Serra-Pladevall J, Barberá MJ, Espasa M. *Mycoplasma genitalium* and antibiotic resistance in Spain; the need for an effective response against an emerging problem. Enfermedades Infecciosas y Microbiología Clínica. 2019 [artículo en castellano] [letter to editor]
 32. Fernández-Naval C, Arando M, Espasa M, Antón A, Gimferrer L, Piñana M, **Fernández-Huerta M**, González-López JJ, Serra-Pladevall J, Pumarola T, Vall-Mayans M, Esperalba J. Novel tp0548 sequence-type of *Treponema pallidum* identified in Barcelona, Spain. Sexually Transmitted Diseases Journal. 2019
 33. Barberá MJ†, **Fernández-Huerta M**†, Jensen JS, Caballero E, Andreu A. *Mycoplasma genitalium* macrolide and fluoroquinolone resistance: prevalence and risk factors among a 2013-2014 cohort of patients in Barcelona, Spain. Sexually Transmitted Diseases Journal. 2017

*Corresponding author

†Co-author

Consejos científicos/editoriales

• Editor Perspectives

2019 - 2021

Sexually Transmitted Infections Journal (BMJ) - British Association for Sexual Health and HIV

"Research news in clinical context":

- doi: 10.1136/sextrans-2019-054270
- doi: 10.1136/sextrans-2019-054273
- doi: 10.1136/sextrans-2019-054275
- doi: 10.1136/sextrans-2020-054858